New study tests Dupilumab's impact on aspirin sensitivity in AERD patients
NCT ID NCT05031455
First seen Apr 28, 2026 · Last updated May 12, 2026 · Updated 1 time
Summary
This study looked at how dupilumab, a drug for asthma and nasal polyps, changes reactions to aspirin in people with Aspirin-Exacerbated Respiratory Disease (AERD). Sixteen adults already taking dupilumab for at least 12 weeks underwent an aspirin challenge to see if they had fewer or milder reactions. The goal was to understand if dupilumab can make aspirin desensitization safer or easier.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASPIRIN-EXACERBATED RESPIRATORY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scripps Clini
San Diego, California, 92130, United States
Conditions
Explore the condition pages connected to this study.